Kidney (Renal Cell) Cancer

    Actionable Target Abnormality Prevalence Clinical Experience with Targeted Agent
    c-MET Mutation (increases transcription of angiogenesis and growth factor receptors) In addition to MET mutations, copy number gain of chromosome 7 (containing loci of both the MET receptor gene, MET, and its ligand, HGF) is common, occurring in 45%–75% of sporadic PRCC cases, and copy number alterations of MET occur in 81% of type 1 and 46% of type 2 PRCCs Savolitinib:
    • Phase 2: RR 18% of papillary RCC pts with MET-driven disease vs. 0% with MET-independent disease, PFS vs. 1.4 mo (1)
    Other topics in Targets by Organ Site